| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A boost for personalised medicine
|
The Lancet Haematology,
|
|
2015
|
2 |
3 |
p. e82-
1 p.
|
artikel
|
| 2 |
First-line therapy for CML: decisions, decisions
|
Davies, Jeff
|
|
2015
|
2 |
3 |
p. e89-e90
nvt p.
|
artikel
|
| 3 |
HSCT: navigating the journey ahead
|
Copelan, Edward
|
|
2015
|
2 |
3 |
p. e83-e84
nvt p.
|
artikel
|
| 4 |
Is another antibody conjugate against ALL needed?
|
Wayne, Alan S
|
|
2015
|
2 |
3 |
p. e87-e88
nvt p.
|
artikel
|
| 5 |
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
|
Jain, Preetesh
|
|
2015
|
2 |
3 |
p. e118-e128
nvt p.
|
artikel
|
| 6 |
One million haemopoietic stem-cell transplants: a retrospective observational study
|
Gratwohl, Alois
|
|
2015
|
2 |
3 |
p. e91-e100
nvt p.
|
artikel
|
| 7 |
Safety and efficacy of allogeneic umbilical cord red blood cell transfusion for children with severe anaemia in a Kenyan hospital: an open-label single-arm trial
|
Hassall, Oliver W
|
|
2015
|
2 |
3 |
p. e101-e107
nvt p.
|
artikel
|
| 8 |
Umbilical cord blood transfusions in low-income countries
|
Gluckman, Eliane
|
|
2015
|
2 |
3 |
p. e85-e86
nvt p.
|
artikel
|
| 9 |
90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study
|
Chevallier, Patrice
|
|
2015
|
2 |
3 |
p. e108-e117
nvt p.
|
artikel
|
Tijdschrift beschrijving